Avaxia Biologics' Series B - II Round

Avaxia Biologics raised a round of funding on June 07, 2013.

Avaxia is an early-stage biotechnology company focused on developing recombinant, gut-targeted antibody therapeutics for gastrointestinal diseases. These unique antibody therapeutics, called Avaximabs…

Articles about Avaxia Biologics' Series B - II Round: